Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations
- Author(s)
- Lim, AM; Le Tourneau, C; Hurt, C; Laskar, SG; Steuer, CE; Chow, VLY; Szturz, P; Henson, C; Day, AT; Bates, JE; Lazarakis, S; McDowell, L; Mehanna, H; Yom, SS; HNCIG;
- Details
- Publication Year 2024-07,Volume 25,Issue #7,Page e308-e317
- Journal Title
- Lancet Oncology
- Publication Type
- Review
- Abstract
- Transparent and precise endpoint definitions are a crucial aspect of clinical trial conduct and reporting, and are used to communicate the benefit of an intervention. Previous studies have identified inconsistencies in endpoint definitions across oncological clinical trials. Here, the Head and Neck Cancer International Group assessed endpoint definitions from phase 3 trials or trials considered practice-changing for patients with recurrent or metastatic mucosal head and neck squamous cell carcinoma, published between 2008 and 2021. We identify considerable and global heterogeneity in endpoint definitions, which undermines the interpretation of results and development of future studies. We show how fundamental components of even incontrovertible endpoints such as overall survival vary widely, highlighting an urgent need for increased rigour in reporting and harmonisation of endpoints.
- Publisher
- Elsevier
- Keywords
- Humans; *Squamous Cell Carcinoma of Head and Neck/pathology/mortality/secondary/therapy; *Neoplasm Recurrence, Local/pathology; *Consensus; *Head and Neck Neoplasms/pathology/mortality/therapy; *Endpoint Determination/standards; Clinical Trials, Phase III as Topic; Neoplasm Metastasis
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1016/s1470-2045(24)00068-8
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-08-06 05:29:23
Last Modified: 2024-08-06 05:31:19